MeiraGTx's Parkinson's Disease Therapy Shows Improvement in Motor Examination Score

MT Newswires Live10-15

MeiraGTx Holdings (MGTX) said Tuesday that data from a study of its experimental Parkinson's disease treatment, AAV-GAD, showed a statistically significant improvement in motor examination score in the high-dose group compared with no significant change in the sham or low-dose groups.

The drug also significantly improved the disease-specific, patient-reported quality of life measures in both the high and low-dose groups, with no substantial change in the sham group.

AAV-GAD was safe and well tolerated, with no serious adverse events reported.

The company plans to use the study's data for discussions with regulators in the US, Europe, and Japan to initiate a global Phase 3 study.

MeiraGTx shares jumped more than 12% in premarket trading.

Price: 5.2100, Change: +0.57, Percent Change: +12.28

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2475082185?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-15 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475082185","market":"sh","top_or_hot":-1,"title":"MeiraGTx's Parkinson's Disease Therapy Shows Improvement in Motor Examination Score","media":"MT Newswires Live","content":"<html><body><p> MeiraGTx Holdings (MGTX) said Tuesday that data from a study of its experimental Parkinson's disease treatment, AAV-GAD, showed a statistically significant improvement in motor examination score in the high-dose group compared with no significant change in the sham or low-dose groups.</p><p>The drug also significantly improved the disease-specific, patient-reported quality of life measures in both the high and low-dose groups, with no substantial change in the sham group.</p><p>AAV-GAD was safe and well tolerated, with no serious adverse events reported.</p><p>The company plans to use the study's data for discussions with regulators in the US, Europe, and Japan to initiate a global Phase 3 study.</p><p>MeiraGTx shares jumped more than 12% in premarket trading.</p><p>Price: 5.2100, Change: +0.57, Percent Change: +12.28</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MeiraGTx's Parkinson's Disease Therapy Shows Improvement in Motor Examination Score</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeiraGTx's Parkinson's Disease Therapy Shows Improvement in Motor Examination Score\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-15 20:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>MeiraGTx Holdings (MGTX) said Tuesday that data from a study of its experimental Parkinson's disease treatment, AAV-GAD, showed a statistically significant improvement in motor examination score in ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MGTX","symbol_name":"Meiragtx Holdings Plc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2475082185","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475082185","pubTimestamp":1728993681,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"MeiraGTx Holdings  said Tuesday that data from a study of its experimental Parkinson's disease treatment, AAV-GAD, showed a statistically significant improvement in motor examination score in the high-dose group compared with no significant change in the sham or low-dose groups.The drug also significantly improved the disease-specific, patient-reported quality of life measures in both the high and low-dose groups, with no substantial change in the sham group.AAV-GAD was safe and well tolerated, with no serious adverse events reported.The company plans to use the study's data for discussions with regulators in the US, Europe, and Japan to initiate a global Phase 3 study.MeiraGTx shares jumped more than 12% in premarket trading.Price: 5.2100, Change: +0.57, Percent Change: +12.28","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MGTX":"Meiragtx Holdings Plc","BK4139":"生物科技"},"translate_title":"MeiraGTx帕金森病疗法显示运动检查评分改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MGTX":0.9},"content_text":"MeiraGTx Holdings (MGTX) said Tuesday that data from a study of its experimental Parkinson's disease treatment, AAV-GAD, showed a statistically significant improvement in motor examination score in the high-dose group compared with no significant change in the sham or low-dose groups.The drug also significantly improved the disease-specific, patient-reported quality of life measures in both the high and low-dose groups, with no substantial change in the sham group.AAV-GAD was safe and well tolerated, with no serious adverse events reported.The company plans to use the study's data for discussions with regulators in the US, Europe, and Japan to initiate a global Phase 3 study.MeiraGTx shares jumped more than 12% in premarket trading.Price: 5.2100, Change: +0.57, Percent Change: +12.28","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2475082185"}